Pubblicazioni

Pulmonary hypertension in patients with COPD. results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA)

2021 - CHEST

Vizza, C. D.; Hoeper, M. M.; Huscher, D.; Pittrow, D.; Benjamin, N.; Olsson, K. M.; Ghofrani, H. A.; Held, M.; Klose, H.; Lange, T.; Rosenkranz, S.; Dumitrescu, D.; Badagliacca, R.; Claussen, M.; Halank, M.; Vonk-Noordegraaf, A.; Skowasch, D.; Ewert, R.; Gibbs, J. S. R.; Delcroix, M.; Skride, A.; Coghlan, G.; Ulrich, S.; Opitz, C.; Kaemmerer, H.; Distler, O.; Grunig, E.

Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension. clinical and haemodYnamic long-term efficacy (ITALY study)

2018 - JOURNAL OF CARDIOVASCULAR MEDICINE

D'alto, M.; Romeo, E.; Argiento, P.; Paciocco, G.; Prediletto, R.; Ghio, S.; Correale, M.; Lo Giudice, F.; Badagliacca, R.; Greco, A.; Vizza, C. D.

Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension

2015 - LUNG

Lichtblau, Mona; Harzheim, Dominik; Ehlken, Nicola; Marra, Alberto; Pinado, Fabiola Pena; GrÃ¼nig, Ekkehard; Egenlauf, Benjamin